Kathleen Farry-Leggiero, MD
Family Medicine · Syracuse, NYNPI 1699334318
Payments from drug & device makers
Across 247 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$374
- GSK$316
- Lilly USA, LLC$314
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$313
- Johnson & Johnson$308
- Novo Nordisk$260
- plus $3K from 30 others
What the payments were for
- Food & beverage$4,656100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $374 |
| GSK | 20 | $316 |
| Lilly USA, LLC | 18 | $314 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $313 |
| Johnson & Johnson | 16 | $308 |
| Novo Nordisk | 16 | $260 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $243 |
| Madrigal Pharmaceuticals | 6 | $211 |
| AstraZeneca | 11 | $196 |
| Exact Sciences | 11 | $182 |
| Shield Therapeutics Inc | 8 | $163 |
| Kyowa Kirin, Inc. | 6 | $152 |
| Pfizer | 9 | $152 |
| Merck | 7 | $123 |
| Bayer | 6 | $119 |
| Astellas Pharma US Inc | 4 | $111 |
| Corcept Therapeutics | 5 | $106 |
| Idorsia Pharmaceuticals US Inc | 6 | $98 |
| Otsuka America Pharmaceutical, Inc. | 5 | $90 |
| Abbott | 2 | $87 |
| Amgen | 5 | $79 |
| Teva Pharmaceuticals USA, Inc. | 2 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $73 |
| Insulet Corporation | 3 | $69 |
| Edwards Lifesciences | 3 | $67 |
| Gilead | 3 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Tactile Systems Technology Inc | 1 | $33 |
| Corium, LLC | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| IBSA Pharma Inc. | 1 | $16 |
How this compares
$4,656 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $87,475 |
| JardianceEmpagliflozin | 53 | $67,118 |
| TrulicityDulaglutide | 48 | $49,137 |
| JanuviaSitagliptin Phosphate | 30 | $35,413 |
| EliquisApixaban | 26 | $29,193 |
| MounjaroTirzepatide | 17 | $21,371 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,523 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,727 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,941 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,226 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $3,791 |
| Atorvastatin Calcium | 301 | $2,600 |
| Levothyroxine Sodium | 185 | $1,950 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,744 |
| Omeprazole | 126 | $1,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $260 | $87,47573 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $314 | $70,50965 claims |
| Boehringer IngelheimJardiance | $20 | $67,11853 claims |
| MerckJanuvia | $123 | $35,41330 claims |
| PfizerEliquis | $152 | $29,19326 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $316 | $25,19150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Syracuse
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.